Literature DB >> 9184181

Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues.

D J Howarth1, I B Aronson, E P Diamandis.   

Abstract

Prostate-specific antigen (PSA), a glycoprotein initially thought to be produced only by the epithelial cells of the prostate, has recently been found in 30% of female breast tumours using immunofluorometry. Our aim was to localize PSA immunohistochemically in a selected group of 27 paraffin-embedded breast tissues. A scoring system was developed for the histological assessment of PSA positivity within the breast tissue. One pathologist (DH) scored, classified and graded all tumours. Site-specific PSA staining was noted in the histology slides. Intense staining was identified in apocrine metaplasia and within the lining ductal epithelium of cystically dilated ducts. The epithelium in lesions of sclerosing adenosis was also frequently positive for PSA staining. Hyperplastic ductal epithelium (especially of mild degree) occasionally stained positive, as did normal breast ducts. Better differentiated tumours showed PSA staining [e.g. mucinous carcinoma (colloid)]. If an infiltrating duct carcinoma showed staining for PSA, adjacent intraductal carcinoma was also noted to stain positively, if present.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184181      PMCID: PMC2223538          DOI: 10.1038/bjc.1997.280

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Authors:  H Yu; E P Diamandis; M Levesque; M Giai; R Roagna; R Ponzone; P Sismondi; M Monne; C M Croce
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry.

Authors:  J H van Krieken
Journal:  Am J Surg Pathol       Date:  1993-04       Impact factor: 6.394

3.  The 'female prostate': location, morphology, immunohistochemical characteristics and significance.

Authors:  N Wernert; M Albrech; I Sesterhenn; R Goebbels; H Bonkhoff; G Seitz; R Inniger; K Remberger
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

4.  Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies.

Authors:  H Yu; E P Diamandis
Journal:  Clin Chem       Date:  1993-10       Impact factor: 8.327

Review 5.  Prostate cancer: screening and early detection update.

Authors:  N S Berger
Journal:  Semin Oncol Nurs       Date:  1993-08       Impact factor: 2.315

6.  Purification of a human prostate specific antigen.

Authors:  M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Invest Urol       Date:  1979-09

Review 7.  Prostate-specific antigen: biochemistry, analytical methods, and clinical application.

Authors:  D A Armbruster
Journal:  Clin Chem       Date:  1993-02       Impact factor: 8.327

8.  Prostate-specific antigen in milk of lactating women.

Authors:  H Yu; E P Diamandis
Journal:  Clin Chem       Date:  1995-01       Impact factor: 8.327

9.  Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age.

Authors:  H Yu; E P Diamandis; D J Sutherland
Journal:  Clin Biochem       Date:  1994-04       Impact factor: 3.281

10.  Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary.

Authors:  H Yu; E P Diamandis; M Levesque; P Sismondi; P Zola; D Katsaros
Journal:  J Clin Lab Anal       Date:  1994       Impact factor: 2.352

View more
  8 in total

1.  The effective management of biochemical recurrence in patients with prostate cancer.

Authors:  David G McLeod
Journal:  Rev Urol       Date:  2005

2.  Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.

Authors:  J Romppanen; R Keskikuru; V Kataja; M Eskelinen; V M Kosma; K Savolainen; M Uusitupa; I Mononen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

3.  Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Authors:  Ilka Kristiansen; Carsten Stephan; Klaus Jung; Manfred Dietel; Anja Rieger; Yuri Tolkach; Glen Kristiansen
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

4.  Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.

Authors:  Prashant D Tailor; Sai Karthik Kodeboyina; Shan Bai; Nikhil Patel; Shruti Sharma; Akshay Ratnani; John A Copland; Jin-Xiong She; Ashok Sharma
Journal:  Oncotarget       Date:  2018-04-03

5.  Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.

Authors:  R E Hall; J A Clements; S N Birrell; W D Tilley
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

6.  Expression of androgen receptor and prostate-specific antigen in male breast carcinoma.

Authors:  Noman Kidwai; Yun Gong; Xiaoping Sun; Charuhas G Deshpande; Anjana V Yeldandi; M Sambasiva Rao; Sunil Badve
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

7.  Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.

Authors:  Masanori Noguchi; Noriko Koga; Fukuko Moriya; Shigetaka Suekane; Shigeru Yutani; Akira Yamada; Shigeki Shichijo; Tatuyuki Kakuma; Kyogo Itoh
Journal:  Cancer Sci       Date:  2018-07-23       Impact factor: 6.716

8.  Clinical significance of serum PSA in breast cancer patients.

Authors:  Toru Hanamura; Koichi Ohno; Shinya Hokibara; Hideki Murasawa; Toshitsugu Nakamura; Hidehiko Watanabe; Machiko Kaizuka; Shinji Sawano; Hiroshi Koyama; Ken-Ichi Ito
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.